. "Simvastatin"@en . "3 hours"@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "Synvinolin"@en . . . . . . . . . . . . . . . "Simvastatin can cross the blood-brain-barrier. "@en . . . . . . . . . . . . . "For the treatment of hypercholesterolemia and for the reduction in the risk of cardiac heart disease mortality and cardiovascular events. It can also be used in adolescent patients for the treatment of heterozygous familial hypercholesterolemia. "@en . . . . . "Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces."@en . . "Both simvastatin and its \u03B2-hydroxyacid metabolite are highly bound (approximately 95%) to human plasma proteins."@en . . "The most common adverse reactions that lead to discontinuation of therapy include gastrointestinal disorders (0.5%), myalgia (0.1%), and arthralgia (0.1%). "@en . . . . " "@en . . . . "Shieh-Shung J. Chen, Byron H. Arison, \"Process for the preparation of 3-keto, 5-hydroxy simvastatin analogs.\" U.S. Patent US4965200, issued April, 1981."@en . . . "Humans and other mammals"@en . . . "# Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE: Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med. 2007 Jul 19;5:20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17640385"@en . "Zocor"@en . "Simvastatin"@en . . . . "Avoid alcohol."@en . . "approved"@en . . . . "Avoid drastic changes in dietary habit."@en . "79902-63-9"@en . "Absorption of simvastatin, estimated relative to an intravenous reference dose, in each of two animal species tested, averaged about 85% of an oral dose. In animal studies, after oral dosing, simvastatin achieved substantially higher concentrations in the liver than in non-target tissues. However, because simvastatin undergoes extensive first-pass metabolism, the availability of the drug in the systemic is low. Peak plasma concentration occurs 1.3 - 2.4 hours after administration. "@en . "Simvastatinum"@en . . . . . . . . . . . . . . . . . . . . . . . "MK-733"@en . . . "Simvastatin is a prodrug in which the 6-membered lactone ring of simvastatin is hydrolyzed in vivo to generate the beta,delta-dihydroxy acid, an active metabolite structurally similar to HMG-CoA (hydroxymethylglutaryl CoA). Once hydrolyzed, simvastatin competes with HMG-CoA for HMG-CoA reductase, a hepatic microsomal enzyme. Interference with the activity of this enzyme reduces the quantity of mevalonic acid, a precursor of cholesterol."@en . . . . . . . . . . . . . . "Simvastatin is a lipid-lowering agent that is derived synthetically from the fermentation of Aspergillus terreus. It is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (hydroxymethylglutaryl COA reductases), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL receptors, it increases breakdown of LDL cholesterol. [PubChem]"@en . . . . . . . . . . "Simvastatina"@en . . . . . . . . . . . . . . . . . . . . . . . . . . . "2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one"@en . . . . "Avoid taking with grapefruit juice."@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "Simvastatine"@en . . . . . . . .